BIOPHYTIS (EPA:ALBPS) - Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami

Transparency directive : regulatory news

01/03/2018 07:45

Press release

Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and
presents four posters at the International Conference on Frailty & Sarcopenia
Research (ICFSR) in Miami

Paris (France), March 1st, 2018, 7.45am - BIOPHYTIS (Euronext Growth Paris:
ALBPS), a biotechnology company specializing in the development of drug
candidates to treat age-related diseases, today announces that it will present
four posters and will give two oral presentations in the treatment of
Sarcopenia at the 8th International Conference on Frailty & Sarcopenia
Research, held March 1st-3rd 2018 in Miami, United States. These results
demonstrate the strong potential of Sarconeos (BIO101) in the treatment of
Sarcopenia and confirm the relevance of the SARA-INT international clinical
study, in which the first patient will be enrolled in the coming weeks.

Stanislas Veillet, CEO of BIOPHYTIS, comments: "We are proud to provide an
update on the progress of the SARA clinical study and to present original
results confirming the strong potential of Sarconeos (BIO101) in the treatment
of sarcopenia. A poster highlights exciting data, demonstrating that the
efficacy of Sarconeos in improving muscle function requires the stimulation of
muscular anabolism and energy metabolism, which explains the remarkable effect
observed on mobility in animal models. In addition, for the first time, we are
presenting the first results of SARA-OBS study, which allows us to monitor up
to one hundred sarcopenic patients in a dozen clinical centers in the United
States and Europe for 6 months, evaluating physical activity by actimetry.
These patients are expected to be included in the SARA-INT interventional
study, the first patients being enrolled in the coming weeks, first in Belgium
and the United States, for which we obtained the approvals at the end of
2017."

Oral presentations and posters that will be presented at the ICFSR provide an
update on the progress of SARA study of Sarconeos (BIO101) in sarcopenia and
present original results on the mechanisms of action of Sarconeos (BIO101) and
BIO103, the second-generation compound in preclinical development for the
treatment of muscular dystrophies:

* The SARA-OBS clinical study evaluates the mobility, strength and physical
activity of up to one hundred sarcopenic patients recruited from a dozen
clinical centers in the United States, Belgium, France and Italy over a 6-month
period. It contributes to a better characterization of patients affected by
this new geriatric indication. The first results of characterization of this
population at inclusion and the first measurements of physical activity by
actimetry will be presented.

* The objective of SARA-INT is to evaluate the safety and the efficacy of two
doses of Sarconeos in the treatment of sarcopenia. The clinical protocol,
meaning inclusion criteria and the main criterion, has been adjusted according
to the scientific advice of the European Medicines Agency (EMA) and the Food &
Drug Administration's (FDA) considerations for the submission of an
Investigational New Drug (IND) application. Biophytis already obtained the
approvals in 2017 from the FDA and the Federal Agency for Medicines and Health
Products (FAMHP) to start this study, and is waiting for approvals from the
French and Italian agencies. The first patients from the SARA-OBS study will be
enrolled in the interventional study in Belgian and American clinical centers
in the coming weeks, once their consent is obtained and new patients will be
recruited in at least 10 new clinical centers currently being opened

* By activating the MAS receptor, Sarconeos (BIO101) stimulates anabolism and
mitochondrial activity of skeletal muscle cells, which explains the effects
observed in animal models not only on muscle mass but also on strength and
mobility.

* BIO103, a second-generation drug candidate in pre-clinical development,
confirms its potential in the treatment of muscle degeneration. BIO103 improves
muscle function in an animal immobilization model, confirming its potential for
the treatment of disuse atrophies.

Oral presentation - Thursday March 1st:

Combined effects of BIO101 on anabolism and mitochondrial function in skeletal
muscle cells
This study demonstrates that the overall beneficial properties of BIO101 on
muscle function rely on both anabolic and mitochondrial effects. Increases in
mitochondrial respiratory spare capacity, in energy metabolism flexibility and
in antioxidant capacity in response to BIO101 exposure are believed to be
responsible for more energy production. These new results are key elements to
better understand the effects of BIO101 in improving running ability of old
mammals and justify the clinical development of Sarconeos in patients with
sarcopenia.

Oral presentation - Saturday March 3rd:

SARA-OBS, an observational study dedicated to characterize age related
sarcopenia population suitable for interventional studies
The SARA-OBS study will contribute to a better characterization of Age-related
Sarcopenia in a community dwelling older patients at risk of mobility
disability. SARA-OBS patients will be used in SARA-INT, to evaluate safety and
efficacy of BIO101.

Posters:

CLINICAL TRIALS

Title:

P110: Daily Mobility profile in Age-Related Sarcopenia: Actimetry baseline data
from SARA-OBS, a six-month observational multicentre clinical study in EU and
US.
Connected actimetry implemented in SARA-OBS allows to gather relevant
information about mobility patterns of the older participants throughout the
trial period without interfering with everyday activity - an innovative
application of the Internet of Things (IOT) to clinical trials.

NEW DRUG DEVELOPMENTS

Title:

P112: Combined effects of BIO101 on anabolism and mitochondrial function in
skeletal muscle cells

This study demonstrates that the overall beneficial properties of BIO101 on
muscle function rely on both anabolic and mitochondrial effects. Increases in
mitochondrial respiratory spare capacity, in energy metabolism flexibility and
in antioxidant capacity in response to BIO101 exposure are believed to be
responsible for more energy production. These new results are key elements to
better understand the effects of BIO101 in improving running ability of old
mammals and justify the clinical development of Sarconeos in patients with
sarcopenia.

Title:

P113: BIO103 demonstrates sharp improvement of skeletal muscle function in an
animal model of hindlimb immobilization

These results demonstrate the efficacy of BIO103 in the prevention of muscle
weight and strength loss in a hindlimb immobilization animal model. BIO103, a
hemisynthetic derivative of Sarconeos could offer a new option for the
treatment of disuse muscle atrophy, which is commonly associated with severe
acute and chronic complications.

Title:

P114: SARA-INT, A double-blind, placebo controlled, randomized clinical trial
to evaluate safety and efficacy of Sarconeos (BIO101) SARA-INT clinical design
is based on the European Medicines Agency scientific advice and FDA IND
considerations.

About SARA-OBS:

SARA-OBS is a multicentric observational study involving up to one hundred
patients over a six-month period in nine clinical centers in Europe and The
United States. The study aims to enrol and characterize a population of
sarcopenic patients who may be included in the SARA-INT study Phase 2b. The
recruitment is carried out according to criteria defined by the Foundation for
the National Institutes of Health: 6mn walk test, 400 meters gait speed test,
electronically recorded patient-reported outcomes (ePROs): SF-36 QOL
questionnaire, measures of muscle strength and muscle mass, plasmatic
biomarkers.

About SARA-INT:

The objective of SARA-INT is to evaluate safety and efficacy of Sarconeos in a
randomized placebo controlled study in patients ≥65 years suffering from
sarcopenia and considered at risk of mobility disability. SARA-INT will
estimate Saroneos effect on decreasing the risk of mobility disability after a
6 months treatment. SARA-INT will take place in 21 sites in EU and US and will
consist of four main visits (baseline, Month1, Month3, and Month6). The main
end-point is the gait speed in the 400-meter walking test. Key secondary
end-points are the questionnaire PF-10 within SF-36 and raising from a chair at
SPPB. Other endpoints include the 6mn distance, body composition, grip strength
and physical activity by actimetry. Patient Reported Outcomes (SF-36, SarQoL
and TSD-OC) and biomarkers of sarcopenia will be also studied. Patients are
selected based on the FNIH criteria (Studenski at al., 2014; SPPB ≤ 8
and ALM/BMI < 0.512 in women and < 0.789 in men or ALM <19.75 kg in men
and <15.02 kg in women. Patients retained from SARA-OBS and newly recruited
will be dosed at Sarconeos- 175 mg b.i.d. and 350 mg b.i.d. during 26 weeks
versus placebo.

About SARCONEOS:

Sarconeos is a first-in-class drug candidate based on the activation of the MAS
receptor (major player of the renin-angiotensin system) restoring muscular
anabolism, inhibiting myostatin, and that had demonstrated meaningful activity
in animal models of muscular dystrophies. Sarconeos is developed in the
treatment of sarcopenia, an age-related degeneration of skeletal muscle,
leading to loss of mobility in elderly people. This condition, for which no
medical treatment currently exists, was first described in 1993 and has entered
the International Classification of Diseases (M62.84) in 2016. It affects more
than 50 million people worldwide.

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates
targeting diseases of aging. Using its technology and know-how, Biophytis has
begun clinical development of innovative therapeutics to restore the muscular
and visual functions in diseases with significant unmet medical needs.
Specifically, the company is advancing two lead products into mid-stage
clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and
Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until
clinical activity in the patient is proven, then to license the technologies in
order to continue the development in partnership with a pharmaceutical
laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and
Marie Curie University) and also collaborates with scientists at the Institute
of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris
(ALBPS; ISIN: FR0012816825).

For more information: http://www.biophytis.com

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

Disclaimer

This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain
forward-looking statements involving risks and uncertainties. The Company's
actual results could differ substantially from those anticipated in these
statements owing to various risk factors which are described in the Company's
prospectus. This press release has been prepared in both French and English. In
the event of any differences between the two texts, the French language version
shall prevail.

BIOPHYTIS
Stanislas VEILLET
CEO
contact@biophytis.com
Tel: +33 (0) 1 44 27 23 00

Citigate Dewe Rogerson
International media & Investors
Laurence BAULT/Antoine DENRY
Laurence.bault@citigatedewerogerson.com
antoine.denry@citigatedewerogreson.com
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

LifeSci Advisors
Chris MAGGOS
Managing Director, Europe
chris@lifesciadvisors.com
Tel: +41 79 367 6254

BIOPHYTIS's latest news

19/04/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories